دورية أكاديمية
أعرض في EDS

Don't eat me/eat me signals as a novel strategy in cancer immunotherapy.

التفاصيل البيبلوغرافية
العنوان: Don't eat me/eat me signals as a novel strategy in cancer immunotherapy.
المؤلفون: Khalaji A; Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.; Liver and Gastrointestinal Diseases Research Center, Tabriz University of Medical Sciences, Tabriz, Iran., Yancheshmeh FB; Cardiac Rehabilitation Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran., Farham F; Faculty of Medicine, Tehran University of Medical Sciences, Tehran, Iran., Khorram A; Department of Laboratory Sciences, School of Allied Medical Sciences, Alborz University of Medical Sciences, Karaj, Iran., Sheshbolouki S; Faculty of Medicine, Hormozgan University of Medical Sciences, Bandar Abbas, Iran., Zokaei M; Department of Food Science and Technology, Faculty of Nutrition Science, Food Science and Technology/National Nutrition and Food Technology Research Institute, Shahid Beheshti University of Medical Sciences, Tehran, Iran.; Department of Veterinary Medicine, Beyza Branch, Islamic Azad University, Beyza, Iran., Vatankhah F; Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran., Soleymani-Goloujeh M; Department of Stem Cells and Developmental Biology, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran.
المصدر: Heliyon [Heliyon] 2023 Sep 29; Vol. 9 (10), pp. e20507. Date of Electronic Publication: 2023 Sep 29 (Print Publication: 2023).
نوع المنشور: Journal Article; Review
اللغة: English
بيانات الدورية: Publisher: Elsevier Ltd Country of Publication: England NLM ID: 101672560 Publication Model: eCollection Cited Medium: Print ISSN: 2405-8440 (Print) Linking ISSN: 24058440 NLM ISO Abbreviation: Heliyon Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: London : Elsevier Ltd, [2015]-
مستخلص: Cancer stands as one of the prominent global causes of death, with its incidence burden continuously increasing, leading to a substantial rise in mortality rates. Cancer treatment has seen the development of various strategies, each carrying its drawbacks that can negatively impact the quality of life for cancer patients. The challenge remains significant within the medical field to establish a definitive cancer treatment that minimizes complications and limitations. In the forthcoming years, exploring new strategies to surmount the failures in cancer treatment appears to be an unavoidable pursuit. Among these strategies, immunology-based ones hold substantial promise in combatting cancer and immune-related disorders. A particular subset of this approach identifies "eat me" and "Don't eat me" signals in cancer cells, contrasting them with their counterparts in non-cancerous cells. This distinction could potentially mark a significant breakthrough in treating diverse cancers. By delving into signal transduction and engineering novel technologies that utilize distinct "eat me" and "Don't eat me" signals, a valuable avenue may emerge for advancing cancer treatment methodologies. Macrophages, functioning as vital components of the immune system, regulate metabolic equilibrium, manage inflammatory disorders, oversee fibrosis, and aid in the repair of injuries. However, in the context of tumor cells, the overexpression of "Don't eat me" signals like CD47, PD-L1, and beta-2 microglobulin (B2M), an anti-phagocytic subunit of the primary histocompatibility complex class I, enables these cells to evade macrophages and proliferate uncontrollably. Conversely, the presentation of an "eat me" signal, such as Phosphatidylserine (PS), along with alterations in charge and glycosylation patterns on the cellular surface, modifications in intercellular adhesion molecule-1 (ICAM-1) epitopes, and the exposure of Calreticulin and PS on the outer layer of the plasma membrane represent universally observed changes on the surface of apoptotic cells, preventing phagocytosis from causing harm to adjacent non-tumoral cells. The current review provides insight into how signaling pathways and immune cells either stimulate or obstruct these signals, aiming to address challenges that may arise in future immunotherapy research. A potential solution lies in combination therapies targeting the "eat me" and "Don't eat me" signals in conjunction with other targeted therapeutic approaches. This innovative strategy holds promise as a novel avenue for the future treatment of cancer.
Competing Interests: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
(© 2023 The Authors.)
References: Eur J Immunol. 2016 Jul;46(7):1681-90. (PMID: 27109306)
Glycobiology. 2014 Sep;24(9):800-6. (PMID: 24996822)
Immunol Rev. 2009 Mar;228(1):342-59. (PMID: 19290938)
Science. 2013 Jul 5;341(6141):88-91. (PMID: 23722425)
Adv Drug Deliv Rev. 2016 Apr 1;99(Pt A):2-11. (PMID: 26826436)
J Nanobiotechnology. 2020 Sep 3;18(1):122. (PMID: 32883290)
Cell Death Differ. 2016 Jun;23(6):952-61. (PMID: 26891692)
Nat Med. 2007 Jan;13(1):54-61. (PMID: 17187072)
Methods Mol Biol. 2015;1313:141-8. (PMID: 25947662)
Apoptosis. 2019 Apr;24(3-4):245-255. (PMID: 30929105)
Nat New Biol. 1972 Mar 1;236(61):11-2. (PMID: 4502419)
Sci Transl Med. 2019 Feb 13;11(479):. (PMID: 30760579)
Biol Reprod. 2008 Apr;78(4):586-94. (PMID: 18057312)
Nat Immunol. 2018 Jan;19(1):76-84. (PMID: 29180808)
Science. 2000 Jun 16;288(5473):2051-4. (PMID: 10856220)
Nature. 2019 May;569(7755):222-228. (PMID: 30971824)
Eur J Immunol. 2000 Aug;30(8):2130-7. (PMID: 10940903)
J Immunol. 1998 Jun 1;160(11):5404-9. (PMID: 9605141)
Front Immunol. 2020 Jul 17;11:1324. (PMID: 32765491)
Exp Cell Res. 2017 Oct 15;359(2):449-457. (PMID: 28830685)
J Leukoc Biol. 2002 Aug;72(2):239-48. (PMID: 12149414)
Nat Immunol. 2013 Oct;14(10):996-1006. (PMID: 24048121)
Curr Opin Immunol. 2012 Apr;24(2):225-32. (PMID: 22310103)
Physiol Rev. 2016 Apr;96(2):605-45. (PMID: 26936867)
Nat Rev Immunol. 2008 Jan;8(1):34-47. (PMID: 18064051)
Am J Pathol. 2007 Jul;171(1):2-8. (PMID: 17591947)
Traffic. 2015 Jan;16(1):35-47. (PMID: 25284293)
Immunol Rev. 2017 Mar;276(1):145-164. (PMID: 28258703)
Proc Natl Acad Sci U S A. 2011 Nov 29;108(48):19246-51. (PMID: 22084121)
Nat Rev Cancer. 2019 Oct;19(10):568-586. (PMID: 31462760)
Immunol Rev. 2015 Nov;268(1):66-73. (PMID: 26497513)
Immunol Rev. 2008 Aug;224:11-43. (PMID: 18759918)
Nat Rev Immunol. 2014 Mar;14(3):166-80. (PMID: 24481336)
Proc Natl Acad Sci U S A. 2012 Apr 24;109(17):6656-61. (PMID: 22451919)
CA Cancer J Clin. 2021 May;71(3):209-249. (PMID: 33538338)
J Immunol. 1997 Dec 1;159(11):5192-6. (PMID: 9548455)
Biochemistry (Mosc). 2022 Mar;87(3):191-206. (PMID: 35526851)
J Mol Biol. 2006 Jan 13;355(2):237-48. (PMID: 16305801)
Onco Targets Ther. 2020 Sep 22;13:9323-9331. (PMID: 33061420)
Trends Biochem Sci. 2003 Jun;28(6):284-93. (PMID: 12826400)
Biochem Soc Trans. 2022 Oct 31;50(5):1281-1291. (PMID: 36281986)
Oncotarget. 2015 Sep 15;6(27):23662-70. (PMID: 26093091)
Nature. 2019 Aug;572(7769):392-396. (PMID: 31367043)
PLoS One. 2017 Oct 30;12(10):e0187262. (PMID: 29084248)
Front Immunol. 2019 May 03;10:962. (PMID: 31130954)
J Biol Chem. 2000 Dec 1;275(48):37984-92. (PMID: 10964914)
Annu Rev Immunol. 2013;31:51-72. (PMID: 23157435)
J Immunol. 2008 Feb 15;180(4):2329-38. (PMID: 18250442)
Front Immunol. 2020 Mar 31;11:553. (PMID: 32296442)
Nat Rev Mol Cell Biol. 2018 May;19(5):281-296. (PMID: 29410529)
PLoS One. 2015 Sep 21;10(9):e0137345. (PMID: 26390038)
J Extracell Vesicles. 2020 Aug 19;9(1):1806444. (PMID: 32944191)
Chest. 2006 Jun;129(6):1673-82. (PMID: 16778289)
Front Immunol. 2021 Jun 09;12:629979. (PMID: 34177884)
Ann Oncol. 2019 Mar 1;30(3):486-489. (PMID: 30689700)
Cell Commun Signal. 2019 Oct 29;17(1):139. (PMID: 31665027)
Cell Death Differ. 2016 Jun;23(6):979-89. (PMID: 26891690)
Blood. 2012 Jun 14;119(24):5640-9. (PMID: 22535666)
Immunol Rev. 2017 Nov;280(1):149-164. (PMID: 29027226)
J Immunol. 1992 Apr 1;148(7):2207-16. (PMID: 1545126)
Annu Rev Immunol. 1997;15:203-34. (PMID: 9143687)
Annu Rev Biophys. 2010;39:407-27. (PMID: 20192774)
Science. 2000 Oct 6;290(5489):84-9. (PMID: 11021804)
N Engl J Med. 2009 Oct 15;361(16):1570-83. (PMID: 19828534)
Nat Rev Immunol. 2019 Sep;19(9):539-549. (PMID: 31019284)
Cell. 2010 Mar 5;140(5):619-30. (PMID: 20211132)
J Leukoc Biol. 2006 May;79(5):896-903. (PMID: 16641135)
Cancer Immunol Res. 2018 Oct;6(10):1260-1273. (PMID: 30012633)
Cell Res. 2013 Nov;23(11):1247-8. (PMID: 23979019)
Mol Cell. 2004 May 7;14(3):277-87. (PMID: 15125832)
Biol Cell. 2016 Jul;108(7):189-204. (PMID: 27018635)
Annu Rev Immunol. 2009;27:339-62. (PMID: 19302044)
Immunity. 2020 May 19;52(5):742-752. (PMID: 32433947)
Nat Med. 2007 Sep;13(9):1050-9. (PMID: 17704786)
Annu Rev Immunol. 1999;17:593-623. (PMID: 10358769)
Histochem Cell Biol. 2017 May;147(5):565-574. (PMID: 28012129)
Curr Biol. 2021 Jan 11;31(1):77-89.e5. (PMID: 33096038)
J Control Release. 2016 Oct 28;240:332-348. (PMID: 26774224)
J Clin Oncol. 2019 Apr 20;37(12):946-953. (PMID: 30811285)
Front Cell Dev Biol. 2018 Apr 04;6:38. (PMID: 29670880)
J Immunol. 2013 May 15;190(10):5207-15. (PMID: 23596312)
Nat Commun. 2019 Oct 1;10(1):4456. (PMID: 31575859)
Nature. 2009 Sep 10;461(7261):282-6. (PMID: 19741708)
Cancer Immunol Immunother. 2017 Aug;66(8):1079-1087. (PMID: 28638976)
J Cell Biol. 1993 Oct;123(2):485-96. (PMID: 7691831)
Curr Top Microbiol Immunol. 2014;382:373-92. (PMID: 25116109)
Crit Rev Biochem Mol Biol. 2009 Sep-Oct;44(5):264-77. (PMID: 19780638)
J Immunol. 1998 Apr 1;160(7):3562-8. (PMID: 9531319)
J Biol Chem. 1948 Jun;174(2):439-50. (PMID: 18865612)
Cell Cycle. 2014;13(19):2990-1. (PMID: 25486557)
Annu Rev Cell Dev Biol. 2004;20:193-221. (PMID: 15473839)
Cancer Immunol Res. 2019 Feb;7(2):269-281. (PMID: 30563828)
Oncogene. 2016 Nov 17;35(46):5931-5941. (PMID: 27086930)
J Cell Sci. 2009 Jan 15;122(Pt 2):159-63. (PMID: 19118207)
Semin Immunopathol. 2018 Nov;40(6):545-554. (PMID: 30187085)
J Immunol. 1998 Jan 15;160(2):831-7. (PMID: 9551918)
Cell. 2005 Oct 21;123(2):321-34. (PMID: 16239148)
Nat Cell Biol. 2000 Dec;2(12):899-905. (PMID: 11146654)
Clin Immunol. 2019 Jul;204:23-30. (PMID: 30448442)
Theranostics. 2020 Jul 23;10(20):9214-9229. (PMID: 32802188)
Theranostics. 2021 Aug 11;11(18):8738-8754. (PMID: 34522209)
Cell. 2009 Jul 23;138(2):286-99. (PMID: 19632179)
Nature. 2017 Apr 27;544(7651):493-497. (PMID: 28424516)
Front Immunol. 2020 Jan 28;11:18. (PMID: 32082311)
Immunity. 2016 Sep 20;45(3):669-684. (PMID: 27637149)
Sensors (Basel). 2011;11(2):1744-55. (PMID: 22319379)
Nat Commun. 2017 Apr 05;8:14802. (PMID: 28378740)
Sci Transl Med. 2010 Dec 22;2(63):63ra94. (PMID: 21178137)
Nature. 2013 Apr 25;496(7446):445-55. (PMID: 23619691)
Scand J Immunol. 2019 Nov;90(5):e12804. (PMID: 31267559)
Immunity. 2011 Oct 28;35(4):445-55. (PMID: 22035837)
Proc Natl Acad Sci U S A. 2012 Apr 24;109(17):6662-7. (PMID: 22451913)
J Cell Biol. 1990 Dec;111(6 Pt 1):2785-94. (PMID: 2277087)
Exp Cell Res. 2016 Oct 1;347(2):301-11. (PMID: 27539661)
Mol Cell Biol. 2000 May;20(10):3576-89. (PMID: 10779347)
Int J Mol Sci. 2017 Dec 29;19(1):. (PMID: 29286292)
Mol Oncol. 2019 Oct;13(10):2049-2061. (PMID: 31376208)
EMBO Rep. 2021 Jun 4;22(6):e52564. (PMID: 34041845)
J Exp Med. 2010 Aug 30;207(9):1807-17. (PMID: 20805564)
J Biol Chem. 2009 Sep 25;284(39):26613-9. (PMID: 19628875)
Blood. 2001 May 1;97(9):2741-9. (PMID: 11313266)
فهرسة مساهمة: Keywords: Cancer; Don't eat me signal; Eat me signal; Immunotherapy; Phagocytosis
تواريخ الأحداث: Date Created: 20231012 Latest Revision: 20231018
رمز التحديث: 20240628
مُعرف محوري في PubMed: PMC10562801
DOI: 10.1016/j.heliyon.2023.e20507
PMID: 37822610
قاعدة البيانات: MEDLINE
الوصف
تدمد:2405-8440
DOI:10.1016/j.heliyon.2023.e20507